SUMMARY
Dysfunction of ENaC, the epithelial sodium channel that regulates salt and water reabsorption in epithelia, causes several human diseases, including cystic fibrosis (CF). To develop a global understanding of molecular regulators of ENaC traffic/ function and to identify of candidate CF drug targets, we performed a large-scale screen combining highcontent live-cell microscopy and siRNAs in human airway epithelial cells. Screening over 6,000 genes identified over 1,500 candidates, evenly divided between channel inhibitors and activators. Genes in the phosphatidylinositol pathway were enriched on the primary candidate list, and these, along with other ENaC activators, were examined further with secondary siRNA validation. Subsequent detailed investigation revealed ciliary neurotrophic factor receptor (CNTFR) as an ENaC modulator and showed that inhibition of (diacylglycerol kinase, iota) DGKi, a protein involved in PiP2 metabolism, downgrades ENaC activity, leading to normalization of both Na + and fluid absorption in CF airways to non-CF levels in primary human lung cells from CF patients.
INTRODUCTION
ENaC, the epithelial sodium (Na + ) channel is a major player in salt and water reabsorption and epithelial surface hydration in a number of tissues, including airways and alveolar sacs, ducts of exocrine glands, renal collecting duct, and distal colon. ENaC plays a prominent role in lung liquid clearance by the alveolar epithelium after birth by reabsorbing fetal lung fluid (O'Brodovich, 1991) .
As a member of the degenerin ion channel family, ENaC consists of three main subunits, a-, b-and g-ENaC (Canessa et al., 1994) . ENaC impairment leads to diverse diseases with the hallmark of local or systemic imbalance in Na + and water homeostasis. ENaC loss-of-function results for example in renal salt wasting (type I pseudohypoaldosteronism) or pulmonary edema (Berthiaume and Matthay, 2007) . In contrast, ENaC gain-of-function leads to several forms of salt-sensitive hypertension (e.g., Liddle syndrome) or cystic fibrosis (CF) (Bonny and Hummler, 2000; Lifton et al., 2001; Donaldson and Boucher, 2007) . CF is a life-threatening disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein, a chloride (Cl À ) channel localized in the apical membrane of epithelial cells (Riordan, 2008) . Physiologically, CFTR inhibits ENaC and thus regulates pulmonary Na + absorption (Kunzelmann et al., 1995; Gentzsch et al., 2010) . In CF, however, the absence of active CFTR leads to Na + hyperabsorption, which causes dehydration of airway surface liquid (ASL), a hallmark of CF (Boucher, 2007; Mall et al., 1998) . Compelling evidence for the major role that ENaC plays in CF airways came from ßENaC-overexpressing mice, which mimic various aspects of human CF respiratory disease (Mall et al., 2004) . This is in striking contrast to CFTR knockout or CFTR mutant mice, which do not develop lung disease (Snouwaert et al., 1992) . Membrane levels of ENaC are mostly regulated by endocytosis and proteolysis mediated by the E3-ubiquitin-ligase Nedd4-2. Another mouse model, a lung-specific Nedd4-2 knockout, was shown to also develop a CF-like condition (Kimura et al., 2011) , further establishing the key role of ENaC in CF airway disease.
So, along with the search for small molecules to restore CFTR activity, ENaC inhibitors have been sought for CF therapeutics to reduce ENaC-mediated Na + hyperabsorption and increase ASL hydration (Amaral and Kunzelmann, 2007) . Such a goal might also be of interest to treat chronic obstructive lung disease (COPD), disseminated bronchiectasis, or even CFTR dysfunction caused by cigarette smoking (Clunes et al., 2012) . ENaC blockers may also serve to hydrate mucosal surfaces of the gastrointestinal tract, mouth, nose, and eye and treat ENaC gain-of-function conditions, like ENaC-related hypertension (Butterworth et al., 2009) . Amiloride (Amil), used for the management of hypertension and congestive heart failure, was the first ENaC pharmacological inhibitor tested in CF, but studies showed no significant improvement due to its short half-life in the lungs (Knowles et al., 1990) . Longer-acting and more potent ENaC inhibitors (IC 50 $10 nM) include Amil derivatives such as benzamil or PS552 (Parion Sciences, Durham, NC), both yielding disappointing results in CF trials (Donaldson and Boucher, 2007; Hirsh et al., 2006) . Excessive blocking of ENaC may cause severe harm, via undesirable accumulation of fluid in the lungs, i.e., pulmonary edema (Althaus et al., 2011) . Instead, we need compounds normalizing ASL homeostasis through physiological regulation of ENaC. If achieved independently of CFTR, such normalization could correct ion transport in CF patients with any CFTR mutation. Despite detailed knowledge on how several ENaC regulators control both channel number at the cell surface and its open probability (Butterworth et al., 2009 ), many aspects of ENaC biogenesis, trafficking, and regulation remain obscure. Herein, we have undertaken a large-scale loss-of-function (siRNA) screen for ENaC with the ultimate goal of identifying putative druggable targets. We used a live-cell assay and automatic microscopy to functionally assess ENaC in human respiratory epithelial cells after reverse siRNA transfection (Erfle et al., 2007) with libraries targeting a total of 6,396 genes. We thus identified 1,626 genes regulating ENaC: 887 inhibitors and 739 activators. Bioinformatic analyses of primary hits identified the phosphatidylinositol (PI) pathway as the top enriched pathway (with 30 hits), 37% of which were validated. The top $60% primary ENaC-hits also underwent reassessment, achieving $30% validation. (D) Summary of the median ratio Amil-sensitive FMP fluorescence ratios for all spots in the same slide (''slide''), scrambled (''Scrbld''), aENaC and ßCOP siRNA spots. Average of Amil-sensitive ratios (n = 5) is shown as a red line ± SD.
The validated hits were then classified into known ENaC regulatory pathways. Seven genes were found to lie outside such pathways and 2 of these were chosen for further investigation and shown to be key ENaC regulators: diacylglycerol kinase iota (DGKi), a potential robust CF therapeutic target; and ciliary neurotrophic factor receptor (CNTFR), an original ENaC modulator, which proved the screen's power to identify novel hits.
RESULTS
Live-Cell siRNA Screen Identifies 1,626 ENaC Regulators For the high-content siRNA screen, we used a live-cell assay measuring ENaC activity through the voltage-sensitive fluorescent FMP dye in combination with specific ENaC blocker Amil (Almaç a et al., 2011) . Human alveolar epithelial cells A549 (with endogenous ENaC expression) were grown under dexamethasone (Dexa) to maximize ENaC expression (Figures 1A and 1B) (Itani et al., 2002) . Cells were transfected with siRNAs targeting a-ENaC subunit or ßCOP (component of traffic vesicles) as positive controls and scrambled siRNA (Scrbld) as negative control. As expected both a-ENaC and ßCOP siRNAs (but not Scrbld) significantly suppressed the quenching of Amilinduced fluorescence ( Figures 1C and 1D) . The difference between the values for positive (si-aENaC/ si-ßCOP) and Scrbld or ''slide score'' (see Supplemental Information) is relatively modest ($10%). However, due to high reproducibility and lack of overlap between positive and negative controls ( Figure 1D ) we could proceed to high-content microscopy screening. Indeed, the robustness of the microscopy approach and image analysis, allowing collection of cell-based multi-information data (number of cells, removal of debris, apoptotic cells, etc.), enabled quality control, which, together with ''local background'' correction and robust statistics (Chung et al., 2008) led to reliable and reproducible hit discrimination.
For the automated high-throughput microscopy screen, we individually silenced 6,396 protein-coding human genes, using 2-3 siRNAs per gene (n = 17,622) and monitored their effects on ENaC activity by the FMP/Amil assay. The result for each siRNA consisted in the ''slide-normalized spot score'' (''SNS-score'') averaged from siRNA replicates (Dataset S1A available online). SNS-scores were put into an ordered distribution ( Figure 2A ) and siRNAs with SNS-scores % À2 were considered as inhibiting ENaC (Dataset S1B), whereas those with SNS-scores R 2 were considered as activating ENaC (Dataset S1C, Figure 2A ). In summary ( Figure 2C ), this primary screen revealed 1,626 hits: 739 genes activating ENaC, i. e., targeted by siRNAs inhibiting ENaC (highlighted in yellow in Figure 2C ): 711 with one, 27 with two and 1 with 3 siRNAs plus 887 genes inhibiting ENaC, i.e., targeted by ENaC-activating siRNAs: 832 with one, 52 with two and 3 with three siRNAs. All 1,626 ENaC regulator hits were analyzed by DAVID bioinformatic tool for functional annotation, which revealed the phosphatidylinositol (PI) pathway (KEGG hsa04070) as the most significantly enriched with 30 genes, p < 2x10 À6 (Dataset S2 and Figure S1 ). After validation by stringent selection criteria 11 (37%) of these 30 genes could be established as ''truly confirmed'' hits with two or more siRNAs (Dataset S3A and Figure S1 ) PLCB1, PLCZ1) and 1 ENaC inhibitor (PIK3C2B). Although other genes among the 30 had at least two siRNAs that confirmed the primary screen, they also had another siRNA with opposite effect and thus they were not considered as hits.
As we aimed to identify ENaC activators (to be inhibited by small molecules), we also sought for additional siRNA validation of the top 60% ENaC-activating genes (456 out of 739 activator genes). The normalized results of this validation screen are displayed as a scatter plot in Figure 2B and siRNAs below the À1 threshold were considered as hits (gray area, Figure 2B ). This is the minimum normalized score for ''empty spots'' (i.e., positions with lipofectamine only, no siRNA). We thus confirmed 132 ($30%) out of the rescreened 456 primary screen hits (Figure 2C) . These, together with hits targeted by at least two siRNAs in the primary screen, identified 160 ENaC-activator genes ( Figure 2C , Dataset S3B). As most of these hits encode proteins never reported as ENaC regulators, we used Gene Ontology (GO) terms to classify them ( Figure S2 ). We also checked their role in previous screens using the same siRNAs or in other relevant studies (Dataset S3B). Interestingly, the largest group (33%) had been previously implicated in secretory trafficking (Simpson et al., 2012) , followed by 23% in cell division (Neumann et al., 2010) , 5% in plasma membrane targeting of Src kinases (Ritzerfeld et al., 2011) , and 3% in a global set of CFTR interactors (Wang et al., 2006) . Notably, in the latter group we found CFTR itself (plus APC, RYK, HSP90B1, COPB1).
Experimental Hit Classification into Known ENaC Pathways and Further Bioinformatic Analyses
To gain mechanistic insight into how the validated hits regulate ENaC, we performed the same FMP/Amil assay for these genes under conditions that interfere with pathways known to affect ENaC, namely: (1) incubation of cells with protease inhibitor aprotinin to inhibit ENaC activation by proteolytic cleavage (Gaillard et al., 2010) by; (2) under Nedd4-2 siRNA transfection to inhibit ENaC endocytosis mediated by the Nedd4-2/SGK1 pathway (Staub et al., 1997; Debonneville et al., 2001) ; and (3) after induction of WT-(or F508del-) CFTR expression in transduced A549 cells to inhibit (or not) ENaC (Kunzelmann et al., 1995; Almaç a et al., 2011) .
Data in Figure 3A (left graph) show first that aprotinin-treated cells exhibit a modest but consistent and significant decrease ($20%) in the Amil-sensitive ratio versus control cells, as expected due to inhibition of ENaC activation by serine endopeptidases. Second, data show ( Figure 3A , left) that removal of Dexa (6h) already causes significant ENaC inhibition, which, however, can be reverted by Nedd4-2 siRNA with a significant $15% increase versus control cells. Third, induction of WT-CFTR expression (but not of F508del-CFTR) by doxycycline and butyrate (Dox/but), causes a significant decrease in ENaC function of $50% ( Figure 3A , right graph). By recapitulating the in vivo regulation of ENaC by CFTR (Kunzelmann et al., 1995) , these cells are thus very useful to test how the novel ENaC regulators relate to CFTR.
Next, by rescreening the validated ENaC activators under these 3 conditions we classified them according to such pathways (heat-maps in Figure 3B ). For example, under Nedd4-2 downregulation, $56% of the siRNA hits no longer inhibited ENaC (''Nedd4-2-sensitive'' hits) suggesting that they exert their effects on this pathway and indicating the central role that this E3-ubiquitin ligase plays on ENaC regulation. Also, in the presence of aprotinin, $32% of the siRNA hits no longer inhibited ENaC, suggesting that their effects on ENaC are proteasemediated.
Based on their sensitivity to these treatments, the validated hits were grouped into 5 different classes ( Figure 3B and Dataset S4): (1) class I ($23%) insensitive to all treatments; (2) class II ($18%) sensitive to all three treatments; (3) class III, (4) class IV, (5) class V, hits sensitive only to aprotinin ($3%), 6h-Dexa ($13%) or Nedd4-2-siRNA ($23%), respectively. Additional sets (classes VI, VII and VIII) include hits that are sensitive to two out of the three treatments (Dataset S4). Classification of hits according to their CFTR-dependence produced additional classes (marked ''*,''Dataset S4). For example, class IV* includes hits no longer affecting ENaC upon WT-CFTR expression. Of particularly interest are hits showing differential effects in the presence of WT-versus F508del-CFTR (classes IV* and V*) as they may be key to elucidate how WT-CFTR (but not F508del-CFTR) prevents ENaC-mediated Na + hyperabsorption in non-CF individuals. Seven hits were insensitive to all treatments (classes ''I and I*'') namely: ACY3; CCNI; CNTFR; DGKi; IQCF1; MEST; SERPINB3. As they fall out of known ENaC regulatory pathways they deserve further investigation.
To select for putative drug targets and learn more about the validated genes, additional bioinformatic analyses were performed, including a measure of their ''closeness to ENaC,'' given by ''cosine similarity '' values (see Supplemental Information) . This was based on the proteases-Nedd4-2 scores (Dataset S4B) and used as reference values for si-aENaC: the higher the cosine similarity the closer genes are to ENaC (Dataset S5 and Figure S3 ). We also submitted the above 7 ''insensitive'' hits to predictive protein-protein functional correlations (FunL, see Supplemental Information) in relation to ENaC. From the resulting network ( Figure S4 ) two genes emerged functionally closer to ENaC: CNTFR and DGKi. We next selected both genes for further studies.
Although DGK was a recognized ENaC regulator (Kunzelmann et al., 2005) , its DGKi isoform was mechanistically evaluated here as a possible drug target for CF. Indeed, four main reasons led to selection of DGKi: first, DGKi emerged as a key hit in the top-enriched pathway-the PI signaling system ( Figure S1 and Dataset S2); second, the DGKi isoform was found to be highly expressed in human airways ( Figure S5) ; third, bioinformatic analysis ( Figure S3 ) ranked DGKi very close to ENaC (nr.11) even higher than CFTR (nr.14); finally, as a kinase, it is amenable to small-molecule inhibition and thus a good drug target. CNTFR in turn, was also further investigated as an original hit due to its bioinformatic proximity to ENaC (Figures S3 and S4) and to demonstrate the screen's power to identify original hits. DGKi: a Robust Therapeutic Target for ENaC DGKi was thus investigated as a drug target candidate for ENaC regulation and results in various cell types showed that it is essential for maintenance of ENaC activity. First, we showed that a chemical blocker of DGK (DGK inh , 25 mM) led to $50% ENaC inhibition in A549 cells (Figures 4A and 4B) . Second, in mouse tracheas assessed ex vivo in Ussing chambers, DGK inh attenuated Amil-induced voltage deflection and inhibited Amilsensitive short-circuit current, indicating inhibition of ENaC by $60% (Figures 4C and 4D) . Third, these data were confirmed in polarized H441 human airway epithelial cells and M1 mouse collecting duct cells (data not shown), as well as after coexpression of three ENaC subunits (abg) in Xenopus oocytes, where the Amil-inhibited whole-cell conductance (G Amil ) was $30% inhibited by DGK inh ( Figure 4E, left bar) .
To better understand the underlying mechanisms, we assessed ENaC conductance in Xenopus oocytes, by coexpressing DGKi and WT-or truncated (a H648X ) aENaC with WTbgENaC. We found that $60% of G Amil produced by a H648X bgENaC was inhibited by DGK inh , in contrast to only $30% for abgENaC ( Figure 4E ). The truncated a H648X lacks an essential binding site for the ubiquitin ligase Nedd4-2, resulting in enhanced ENaC-activity (G Amil = 107.27 ± 26.4 versus 47.25 ± 4.8 mS) that is fully subjected to regulation by PIP 2 and DGK inh (Yue et al., 2002; Kunzelmann et al., 2005) . The inhibitory effect of DGKi-siRNA on ENaC was therefore augmented becauseNedd4-2-dependent regulation is largely reduced for a H648X bgENaC. In contrast, deletion of the N terminus of b-ENaC largely inhibited ENaC conductance (G Amil = 1.4 ± 0.5 mS) and only $20% of the remaining conductance was inhibited by DGK inh ( Figure 4E , right bar). Because binding of N terminus of b-ENaC to PIP 2 is essential to maintain ENaC activity (Pochynyuk et al., 2007) , these data support the concept that DGK activates ENaC by maintaining sufficiently high PIP 2 levels.
This conclusion was further substantiated by pharmacological manipulation of enzymes that are crucial for PI metabolism and ENaC activity, some of which were hits in the primary screen ( Figure S1 ). Using Amil-sensitive FMP fluorescence in A549 cells as a measure for ENaC activity, siRNA-DGKi was confirmed to inhibit by $50% ENaC activity, whereas Scrbld had no effect ( Figure 4F , black versus white bars, respectively). Inhibition of phospholipase C (PLC) by its blocker U73122, which antagonizes hydrolysis of PIP 2 , completely abrogated the inhibitory effects of siRNA-DGKi on ENaC ( Figure 4F ). In contrast, stimulation of PLC by its activator m3M3FBS inhibited ENaC by $40% and importantly, abolished further inhibition of ENaC by siRNADGKi. These results clearly indicate that DGKi activates ENaC by maintaining the PIP 2 pool in the inner membrane leaflet. The PiP 2 content may also be lowered by phosphatidylinositol-4,5-biphosphate 3-kinase (PI3K) that converts PIP 2 into PIP 3 -phosphatidylinositol (3,4,5)-trisphosphate ( Figure S1 ). Accordingly, inhibition of PI3K by its inhibitor LY294002 slightly reduced ENaC activity because PIP 3 is a positive ENaC regulator (Pochynyuk et al., 2007) . Notably however, in the presence of the PI3K inhibitor, siRNA-DGKi no longer inhibited ENaC ( Figure 4F ), plausibly because of enhanced PIP 2 pools. However, PI3K itself is not a specific target to control ENaC activity because, in contrast to DGK that is confined to the resynthesis of apical PIP 2 , PI3K controls numerous cellular processes (reviewed in Pochynyuk et al., 2008) . DGKi is thus an advantageous target to inhibit ENaC through PIP 2 in the airways because it localizes exclusively to the apical membrane of epithelial cells and in close proximity to ENaC, where it rather specifically controls apically located ion channels. Cells were incubated for 2-5 hr with compounds inhibiting PLC (U73122; 20 mM) or activating PLC (m3M3FBS; 25 mM), inhibiting PI3K (LY294002; 10 mM) or activating PKC (PMA; 10 mM). Mean ± SEM. # , significant difference versus controls (unpaired t test and ANOVA; p < 0.05). See also Figure S5 .
Notwithstanding, inhibition of DGKi also leads to accumulation of DAG, a potent activator of protein kinase C (PKC), which is a known inhibitor of ENaC (Stockand et al., 2000) . To rule out that DGKi-dependent activation of ENaC is associated with DAG-stimulated activation of PKC, we tested the effect of siDGKi on ENaC under PKC modulation. As expected, PKC activation by phorbol 12-myristate 13-acetate (PMA) inhibited ENaC by $50%. However, siRNA-DGKi further reduced ENaC activity, suggesting a PKC-independent inhibitory effect (Figure 4F) . These results are supported by data demonstrating that the PKC-inhibitor bisindolylmaleimide (BIM) is unable to fully restore ENaC activity in si-DGKi treated cells (data not shown). Thus, DGKi activates ENaC by regenerating PIP 2 pools in the inner plasma membrane leaflet.
CNTFR: A Novel ENaC Regulator
Before further investigating CNTFR, we assessed its physiological relevance in the lung by confirming its expression in human native airways ( Figure S6 ). Next, CNTFR expression was knocked-down by siRNA in H441 cells (as confirmed by western blot, Figure S6 ) and this attenuated the effects of Amil on FMP fluorescence ( Figure S6C ) and inhibited Amil-sensitive transport (I eq-Amil ) ( Figures 5A and 5B) . CNTFR couples to several intracellular pathways, one of them being the mammalian target of rapamycin (mTOR) (Yokogami et al., 2000) . Thus, we next inhibited mTOR by rapamycin, which also reduced ENaC-mediated Na + transport ( Figure 5B , left). However, rapamycin itself was without effect on I eq-Amil after si-CNTFR ( Figure 5B , right), suggesting that CNTFR indeed acts through mTOR. CNTFR effects were further validated by its overexpression in Xenopus oocytes, which when coexpressed with ENaC enhanced Amil-sensitive conductance ( Figures 5C and 5D) . Notably, 48 hr incubation of oocytes with the cytokine CNTF (CNTFR ligand) further increased the Amil-sensitive conductance, whereas inhibition of mTOR by rapamycin strongly inhibited ENaC ( Figure 5E ) (Koehl et al., 2010; Ousingsawat et al., 2008) . Thus, CNTF/ CNTFR appears be a novel pathway regulating ENaC operating through mTOR (Lu et al., 2010) . Importantly, ENaC inhibition by si-CNTFR was also confirmed in primary cultures of HBE cells from CF patients ( Figure S6E ).
Validation of DGKi as Drug Target for ENaC in Human CF Airways
Although the above results clearly demonstrate inhibition of ENaC by DGK inh , the crucial question is whether this could be used to inhibit Na + hyperabsorption in CF airways. We therefore isolated airway epithelial cells from lungs of CF patients and grew them as highly differentiated polarized cultures under ALI conditions. Original Ussing chamber recordings demonstrate large Amil-induced voltage deflections, indicating pronounced ENaC activity and Na + absorption in CF airways (Figures 6A and 6C) . ENaC in CF airways is known to be inhibited by stimulation of apical purinergic P2Y 2 receptors, as also shown here by pronounced attenuation of Amil-induced voltage deflections and Amil-sensitive transport (I eq-Amil ) after ATP stimulation. When CF primary cells were treated with DGK inh , Amil-sensitive Na + absorption was largely reduced to its physiological levels (Figures 6B and 6C) . Moreover, ATP-stimulation only slightly further reduced Na + absorption. Remarkably, in non-CF airway cultures, I eq-Amil was lower than in CF airways and DGK inh showed no significant effects on ion transport. These results indicate that enhanced Amil-sensitive Na + absorption is attenuated by DGK inh to levels found in normal non-CF airways, i.e., restoring Na + transport homeostasis but not completely blocking it. DGK inhibitors are therefore a potentially valuable tool for the treatment of CF lung disease. Notably DGK inh also delayed transepithelial fluid absorption in human CF primary epithelial airway cells and again inhibition was more pronounced in CF versus non-CF cells ( Figures S7A and S7B ).
DISCUSSION
The aim of this study was to perform a loss-of-function screen mainly designed to globally identify regulators of ENaC traffic/ function, with the ultimate goal of finding putative drug targets for CF. To this end, we used a high-content siRNA screen whose endpoint was a fluorescent cell-live microscopy assay measuring ENaC activity on an individual cell basis. Analysis of the primary screen data led to the identification of 1,626 ENaC regulators: 739 activator and 887 inhibitor genes. Submission of the primary hits to bioinformatic annotation showed the phosphatidylinositol (PI) signaling system as the most significantly enriched pathway, represented by 30 genes. Evidence of suppression by the siRNAs was previously shown (Neumann et al., 2010) by qRT-PCR tests for >97% of the tested transcripts (see Supplemental Information). Nonetheless, secondary validation of primary hits, i.e., confirmation with additional siRNAs, is vital. Because our main goal was to find new ways of inhibiting ENaC, we focused the hit validation on genes activating ENaC.
We thus selected the top $60% (456) genes out of the 739 ENaC activators and on the 30 genes in the PI pathway. Whereas 160 genes were confirmed by at least two independent siRNAs as ENaC activators in the former group ($30%), 11 genes (37%) from the PI pathway could be validated: ten ENaC activators and one inhibitor. These validation percentages are within the range usually found in similar siRNA screens (Neumann et al., 2010; Simpson et al., 2012) . However, this stringent validation does not completely rule out as ENaC regulators genes that in the primary screen had an effect but could not be confirmed by an independent siRNA. Indeed, other siRNAs acting at higher efficiency may also achieve the effect observed in the primary screen.
Next, we classified the validated hits in relation to the three major known pathways regulating ENaC. The obtained hit classification ( Figure 3B and Dataset S4) may be used to generate multiple hypotheses in various types of analysis. For example, the genes whose siRNAs are sensitive to all three treatments (class II) are probably those responsible for the crosstalking among those three ENaC regulatory pathways. Indeed, the ubiquitination status of ENaC by Nedd4-2, for instance, was shown to affect the proteolytic cleavage of the channel (Ruffieux-Daidié et al., 2008) , but the mechanism is still unknown. Accordingly, the nine genes in class VII (Figure 3B ), i.e., whose siRNA no longer inhibit ENaC under aprotinin nor under Nedd4-2-siRNA, could be related to such crosstalk: KCNQ3, TAS2R1, TNFRSF1B, B4GALT6, KIFAP3, CDK10, GRINA, SCGB3A1, and IFIH1 (Dataset S4). One of these (SCGB3A1) is downregulated in CF nasal epithelium (Clarke et al., 2013) and CF bronchial epithelium (Ogilvie et al., 2011) and upregulated during air-liquid interface differentiation of human bronchial epithelial cells (Ross et al., 2007) .
Also of particular interest are the 11 validated hits (ADAR; AKAP14; ARHGEF11; BRD4; DPP9; KIFAP3; MAST3; PIK3CA; RIPK2; RYK; SCARB2), which no longer inhibited ENaC when WT-CFTR was expressed, but were insensitive to presence of F508del mutant (class IV*, Dataset S4). These genes deserve future examination to elucidate how WT-CFTR (but not F508del-CFTR) prevents the ENaC-mediated Na + hyperabsorption in non-CF individuals. Notably, 4 out of these 11 hits (AKAP14, KIFAP3, MAST3, and ARHGEF11) are cytoskeletonrelated proteins and ARHGEF11 is a regulator of Rho, which we recently showed to be critical for the plasma membrane rescue of F508del-CFTR (Moniz et al., 2013) . Interestingly, these four hits were also found to affect secretory traffic in a previous screen (Simpson et al., 2012) . Although these hit classes are of interest and deserve further examination, detailed investigation of all underlying mechanisms goes well beyond the present study. Nevertheless, we decided to focus on original ENaC activators outside the known pathways (i.e., hits in classes I and I*) as putative drug targets. Among the seven genes in these two classes (Dataset S4)-ACY3; CCNI; CNTFR; DGKi; IQCF1; MEST; and SERPINB3-we selected two for further mechanistic studies: DGKi as a putative drug target and CNTFR as a novel ENaC regulator.
Isoform iota of DGKi, never directly described as an ENaC modulator, was thus further investigated using different approaches, and results indicate that DGKi supports ENaC activity by maintaining PIP 2 levels in the inner plasma membrane leaflet. Indeed, DGKi is a lipid cycle component that is essential for regeneration of phosphatidylinositols such as PIP 2 and our results support the concept that DGK activates ENaC by regenerating the PIP 2 pool present in the inner leaflet of the apical plasma membrane ( Figure 7A ). Negatively charged phosphoinositides like PIP 2 interact with positively charged lysine residues at the N terminus of b-and g-ENaC, which is necessary to keep the channel open (Kunzelmann et al., 2005) . ATP stimulation of purinergic receptors activates PLC and consequently PIP 2 hydrolysis, which leads to ENaC inhibition ( Figure 7B ). Here, we also showed that si-DGKi or its chemical inhibition, reduces ENaC activity to $50% in various cell types and mouse trachea and down to $65% in CF human primary airway cul- , and by lack of ENaC anchoring to PIP 2 via N-terminal lysines (II). Inhibition of DGK depletes the membrane of PIP 2 , thus inhibiting ENaC (III). (B) Binding of CNTF to CNTFR may activate multiple intracellular pathways, leading to suppression of Nedd4-2, which increases activity and membrane expression of ENaC (Koehl et al., 2010) . mTOR upregulates the transcriptional elongation factor elF4F, which is also in charge of postnatal upregulation of ENaC due to increase in O 2 partial pressure (Otulakowski et al., 2007). tures. Notably, attenuation of ENaC by DGK inhibition was pronounced in CF airway cultures but was not significant in non-CF airways. DGK inhibition also caused a delay in transepithelial fluid absorption in CF (but not in non-CF) human primary airway cultures. Importantly, DGKi inhibition in CF primary airway cells does not completely block ENaC activity. Instead, it restores Na + -absorption to normal levels of non-CF airways, a condition that should be fulfilled for potential drugs modulating ENaC. These data demonstrate the physiological relevance of inhibiting DGKi to restore ENaC function, Na + homeostasis, and fluid absorption. As expression levels of DGKi in cultured cells parallel those in native human lung tissues ( Figure S5 ), DGKi appears a physiologically relevant potential drug target for CF. When inhibiting DGK in cells even for long periods of time (up to 72 hr), we did not recognize any obvious toxicity. Moreover the exclusive localization of PIP 2 in the apical membrane (Bryant and Mostov, 2008; Gá lvez-Santisteban et al., 2012) should limit the chance for unexpected effects of DGK inhibitors. Interestingly, this target has been recently proposed to treat inflammation, coagulation, and cancer (Holden et al., 2011; Marumo et al., 2012; Filigheddu et al., 2011) with no reported toxicity.
Taken together, inhibition of DGKi, an original regulator of ENaC activity, seems to constitute a powerful tool to normalize Na + absorption and fluid homeostasis in ASL of CF airways.
There is yet an ongoing controversy with respect to Na + hyperabsorption as the cause of CF lung disease, particularly in light of more recent studies on newborn CF pigs, which cast serious doubt on the concept of hyperabsorption (Chen et al., 2010) . However, studies on human native airways (Boucher et al., 1988; Mall et al., 1998) and ENaC-overexpressing mice (Mall et al., 2004) still clearly support this concept (recently reviewed in Kunzelmann and Schreiber, 2012) . Despite this controversy, inhibition of ENaC has been demonstrated in multiple studies to enhance ASL and to improve mucociliary clearance. Treatment with hypertonic saline, shown to cause ENaC inhibition, has also been demonstrated to improve mucus clearance and lung function (Donaldson et al., 2006) . Another significant hit in the present screen, CNTFR, with no known role in ENaC regulation, was selected to demonstrate the screen's potential to identify unexpected ENaC regulators, and indeed, it was proven to regulate ENaC. Although data here do not fully explore the intracellular pathways leading to ENaC activation through CNTFR, they strongly suggest that CNTFR operates through the mTOR pathway. In fact, earlier studies in mice with enhanced mTOR activity caused by reduced expression of the tumor suppressor APC, demonstrated pronounced upregulation of ENaC (Ousingsawat et al., 2008) . This is probably due to upregulation of the transcriptional elongation factor elF4F, which is also in charge of postnatal ENaC upregulation (Otulakowski et al., 2007) .
Taken together, the present results demonstrate the power of microscopy siRNA screens in discovering novel regulators of ion channels and drug targets. Detailed studies on two screen hits regulating ENaC-DGKi and CNTFR-clearly led to original pathways. Importantly, DGKi seems well-suited as a potential novel drug target for CF because by its inhibition ENaC activity is reduced, and both Na + and fluid absorption are normalized in CF airways to non-CF levels.
EXPERIMENTAL PROCEDURES Materials
The FMP/Amil live-cell assay was previously described (Almaç a et al., 2011) . The siRNAs (n = 17,840) targeting 6,409 different genes (Dataset S1) came from three chemically synthesized libraries: the druggable (Ambion), the kinome (Ambion), and the secretome library (Quiagen), as described (Simpson et al., 2012) . Additional reagents are in Supplemental Information.
Cell Culture
Human alveolar type II epithelial A549 cells (ATCC, Cat no. CCL-185) were grown with or without dexamethasone (Dexa) as before, as well as WT-or F508del-CFTR transduced A549 cells (Almaç a et al., 2011) . More cell culture details are in Supplemental Information.
FMP/Amiloride Assay
The live-cell assay used to identify novel regulators of ENaC activity was performed with the voltage-sensitive dye FMP and 30 mM Amil, as described (Almaç a et al., 2011) on A549 cells reverse-transfected for 48 hr with different siRNAs (Erfle et al., 2007) .
Automated Microscopy and High-Content siRNA Screening Cells ($150,000 cells) were plated in 1.5 ml of culture medium in siRNA prespotted chambered slides. After 48 hr, cells were incubated for 10 min with FMP as described (Almaç a et al., 2011) . Cells on siRNA spots (1-384) were imaged with 103 objective in Cy3 channel, the FMP solution was then automatically replaced by FMP/Amil; after 3 min, the same image acquisition routine started.
Secondary/Validation Screen and Hit Classification into ENaC Pathways
For validation of primary screen hits, we used one to two additional independent siRNAs targeting the top 456 hit genes (targeted by ENaC-inhibiting siRNAs) and performed the same FMP/Amil assay, image quantification, and data analysis as for the primary screen, but with a different normalization (see Supplemental Information). In order to classify the hits into three wellknown ENaC pathways, namely activation by proteolytic cleavage; Nedd4-2-mediated internalization and degradation; and CFTR inhibition, parental A549 cells were submitted to the different treatments detailed in Supplemental Information.
Image Quantification and Primary Screen Data Analysis
For each acquired image the FMP-fluorescence intensity was measured before and after Amil addition using a customized LabView-based program.
Complete details are in Supplemental Information.
Bioinformatic Analysis
The 1,657 primary screen hits (Dataset S1) were submitted to DAVID bioinformatic analysis to identify the biological pathways (from the KEGG database) most significantly overrepresented (Huang et al., 2009) . For GO analysis of validated genes, we used AmiGO (Carbon et al., 2009) . Pathway analysis of the validated screen hits was performed using ENSEMBL IDs (version 61) on ''BioCompendium.'' Bioinformatic analysis details are in Supplemental Information.
Ussing Chamber Experiments
Non-CF and CF primary human bronchial epithelial cells, cultured as described (Supplemental Information), polarized monolayers of H441 or M1 cells were grown on permeable supports (Millipore) for 10 days and then mounted into a perfused micro-Ussing chamber with continuous (luminal and basolateral) perfusion at 5-10 ml/min. Tracheal tissue was isolated from mice. Experiments were carried out under open-circuit conditions at 37 C. Details are in Supplemental Information.
Target Validation by Double-Electrode Voltage-Clamp
Xenopus oocytes were injected with cRNA (10 ng, 47 nl double-distilled water) encoding wild-type abg-ENaC subunits, a-ENaC with a C terminus truncation (a H648X ), and b-ENaC with N terminus deletion (b DN ). Water injected oocytes served as controls. Two to three days after injection, oocytes were impaled with two electrodes as previously described (Kunzelmann et al., 2005) . Unpaired Student's t test or ANOVA were used for statistical analysis, as indicated, and p values lower than 0.05 were accepted as significant.
Plate Reader Experiments
To characterize the mechanism underlying ENaC regulation by DGK, the FMP/ Amil assay was performed on A549 cells using a plate reader (Novostar). A549 cells were transfected with either a scrambled or DGKi-siRNA for 72 hr and the activity of several enzymes involved in phospholipid metabolism and signaling was modulated with specific inhibitors and/or activators (for 2-5 hr)-PLC activator m3M3FBS at 25 mM, PLC inhibitor U73122 at 5 mM, PI3K inhibitor LY294002 at 50 nM, PKC activator PMA at 100 nM, PKC inhibitor BIM at 50 nM. 
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